Generic Name and Formulations:
Thiothixene 1mg, 2mg, 5mg, 10mg; caps.
Indications for Thiothixene:
Individualize. Mild: initially 2mg three times daily, may subsequently increase to 15mg/day. Severe: initially 5mg twice daily. Usual optimal dose: 20–30mg daily; if needed, may increase to max 60mg/day.
Circulatory collapse. Coma. CNS depression. Blood dyscrasias.
Elderly with dementia-related psychosis (not approved use): increased risk of death. History of convulsive disorders or alcohol withdrawal. Exposure to extreme heat. Cardiovascular disease. Pre-existing low WBC or history of drug induced leukopenia/neutropenia; monitor CBCs during 1st few months of treatment. If significant neutropenia occurs; monitor for fever and signs of infections; discontinue if ANC<1000/mm3. Hepatic impairment. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy.
Additive effects with hypotensive agents, CNS depressants and alcohol. Potentiates barbiturates. Antagonized by carbamazepine. Caution with concomitant atropine or related drugs.
Tardive dyskinesia, hypotension, drowsiness, insomnia, jaundice, blood dyscrasias, may mask emetic signs of overdosage or disease, lowered seizure threshold, rash, photosensitivity, hyperprolactinemia, anticholinergic effects, pigmentary retinopathy, lenticular pigmentation, extrapyramidal reactions, neuroleptic malignant syndrome (monitor).
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Predicting Seizure Risk Following Ischemic Stroke With SeLECT Score
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Exome-Targeted Capture Sequencing Can Diagnose Previously-Undetected Ataxia
- Strategies for Preventing and Treating Delirium
- High Total Cholesterol Neuroprotective Against Cognitive Decline